Details of the Drug

General Information of Drug (ID: DMXLVDT)

Drug Name
Lasmiditan
Synonyms COL-144; LY-573144; Migraine therapy, CoLucid
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Approved [1]
ATC Code
N02CC08: Lasmiditan
N02CC: Selective serotonin (5HT1) agonists
N02C: ANTIMIGRAINE PREPARATIONS
N02: ANALGESICS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 377.4
Logarithm of the Partition Coefficient (xlogp) 2.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 1892 +/- 746.0 mcgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 322.8 +/- 122.0 mcg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.8 h [2]
Bioavailability
The bioavailability of drug is 40% [2]
Elimination
Of the small amount of drug found in the urine post-dose, approximately 66% is comprised of lasmiditan's S-M8 metabolite [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 5.7 hours [2]
Metabolism
The drug is metabolized via the hepatic [2]
Chemical Identifiers
Formula
C19H18F3N3O2
IUPAC Name
2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide
Canonical SMILES
CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F
InChI
InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)
InChIKey
XEDHVZKDSYZQBF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
11610526
ChEBI ID
CHEMBL3039520
CAS Number
439239-90-4
UNII
760I9WM792
DrugBank ID
DB11732
TTD ID
D01NQM
ACDINA ID
D01198
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1F receptor (HTR1F) TT0MI3F 5HT1F_HUMAN Agonist [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Lasmiditan
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ubrogepant DM749I3 Moderate Decreased clearance of Lasmiditan due to the transporter inhibition by Ubrogepant. Migraine [8A80] [3]
Rimegepant DMHOAUG Moderate Decreased clearance of Lasmiditan due to the transporter inhibition by Rimegepant. Migraine [8A80] [4]
Coadministration of a Drug Treating the Disease Different from Lasmiditan (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Lasmiditan and Oliceridine. Acute pain [MG31] [5]
ABT-492 DMJFD2I Moderate Decreased clearance of Lasmiditan due to the transporter inhibition by ABT-492. Bacterial infection [1A00-1C4Z] [5]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Lasmiditan and Esketamine. Depression [6A70-6A7Z] [5]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Lasmiditan and Deutetrabenazine. Dystonic disorder [8A02] [5]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Lasmiditan and Ingrezza. Dystonic disorder [8A02] [5]
Eslicarbazepine DMZREFQ Moderate Additive CNS depression effects by the combination of Lasmiditan and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [5]
Ripretinib DM958QB Moderate Decreased clearance of Lasmiditan due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [6]
Belladonna DM2RBWK Moderate Additive CNS depression effects by the combination of Lasmiditan and Belladonna. Infectious gastroenteritis/colitis [1A40] [5]
Berotralstat DMWA2DZ Major Decreased clearance of Lasmiditan due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [7]
Remimazolam DMLVSYX Moderate Additive CNS depression effects by the combination of Lasmiditan and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [5]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Lasmiditan and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [5]
Siponimod DM2R86O Major Increased risk of bradycardia by the combination of Lasmiditan and Siponimod. Multiple sclerosis [8A40] [6]
Rucaparib DM9PVX8 Moderate Decreased clearance of Lasmiditan due to the transporter inhibition by Rucaparib. Ovarian cancer [2C73] [5]
MK-4827 DMLYGH4 Moderate Decreased clearance of Lasmiditan due to the transporter inhibition by MK-4827. Ovarian cancer [2C73] [5]
Relugolix DMK7IWL Major Decreased clearance of Lasmiditan due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [8]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Lasmiditan due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [5]
Betrixaban DM2C4RF Moderate Decreased clearance of Lasmiditan due to the transporter inhibition by Betrixaban. Venous thromboembolism [BD72] [5]
⏷ Show the Full List of 17 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Ferric oxide black E00522 16211978 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Haematite red E00236 14833 Colorant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Lasmiditan 100 mg tablet 100 mg Tablet Oral
Lasmiditan 50 mg tablet 50 mg Tablet Oral
Lasmiditan 200 mg tablet 200 mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 FDA Approved Drugs: Reyvow
3 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
4 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
5 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
6 Cerner Multum, Inc. "Australian Product Information.".
7 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
8 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.